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Abstract 
MicroRNAs or miRNAs are a component of the non-coding RNAs family which is engaged in many cellular functions 
such as cell proliferation, apoptosis, gene expression, signaling pathways, angiogenesis, and etc. Endometriosis is a 
malignant gynecologic disorder occurring in women before menopausal age. Pathogenesis of this illness is still a dis-
cussion subject between the scientists but in our knowledge, microRNAs can be one of the possible involved factors. 
The purpose of this paper is to investigate the role of apoptotic activities of miRNAs in endometriosis. Accumulative 
evidence has demonstrated the role of cell proliferation, apoptosis, and invasion in the progression of these diseases. 
In this review, we looked into the specific role of apoptosis and its related genes and pathways in endometriosis 
and tied to present an explanation of how miRNAs can affect endometriosis by their apoptotic activities. What we 
found is that a great extent of miRNAs is involved in this illness and they are responsible for repressing apoptosis and 
progression of the disease. As a result, miRNAs have two different usages in endometriosis: biomarkers and potential 
therapeutic targets. In this review we gathered a great amount of evidence to inquire into the role of micro RNAs in 
inducing apoptosis and how this mechanism can be exerted for therapeutic purposes for endometriosis.
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Background
Generally, RNAs which are transcribed from the non-
coding parts of the genome can be classified into three 
classes: housekeeping RNAs, transfer RNAs, and regu-
latory RNAs. MicroRNAs (miRNAs) are a kind of small 
regulatory RNAs and are approximately consist of 22 
nucleotides [1, 2]. RNA polymerase II transcripts these 
single-stranded RNAs from DNA, then they get pro-
cessed in the nucleus and after moving to cytoplasm, 
their maturation starts [3]. MiRNAs after completing 
the maturation process by Dicer (RNase III) [4], bind to 
some proteins and produce a ribonucleoprotein complex 
which is involved in silencing the genes and because of 
that it’s called RNA-induced silencing complex (RISC) 
[2]. miRNA binds to the 3′ untranslated region of the tar-
get mRNA and takes its part as a down-regulator for gene 
expression by inhibiting the starting of translation or by 
deterioration of mRNA [5]. Because of this important 
function of miRNAs’, they are involved in some crucial 
processes including: maintenance of stem cells, devel-
opmental timing, metabolism, the interaction between a 
virus and its host, apoptosis, proliferation of the cardiac 
and skeletal muscular cells and expression of the genes 
related to neuronal system [6, 7].
Every month through the menstrual period, endome-
trium gets prepared for the implantation of embryo by 
the means of bearing a class of biological alterations. 
Open Access
Cell & Bioscience
*Correspondence:  shchaichian@gmail.com; asemi_r@yahoo.com
2 Research Center for Biochemistry and Nutrition in Metabolic Diseases, 
Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran
4 Pars Advanced and Minimally Invasive Medical Manners Research 
Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran
Full list of author information is available at the end of the article
Page 2 of 9Taghavipour et al. Cell Biosci           (2020) 10:12 
Inflammatory reactions, programmed cell death, pro-
liferation of the cells, angiogenesis, tissue formation or 
differentiation, and remodeling of the tissues are some 
examples of the engaged processes in altering the endo-
metrium. These processes are regulated by two elements: 
sex steroids secreted from ovaries and products of the 
expression of the local genes. There are also some other 
regulators which their secretion can be autocrine or 
paracrine and include several growth factors, cytokines, 
chemokines, proteases, and extracellular matrix [8–11]. 
Because of the precise expression of this significant regu-
lators, any disturbance can cause an improper regenera-
tion in the endometrium tissue and this may lead to some 
other abnormalities such as endometriosis [8].
Endometriosis is a condition known by ectopic endo-
metrial glands and stroma which has a dependency to 
estrogen and is counted as an inflammatory disorder. 
These ectopic glands and stroma are frequently found in 
pelvis but there are some other locations in which they 
have been observed: the bowel, diaphragm, umbilicus, 
and pleural cavity.
According to evidence, three subtypes are observed 
for endometriosis: superficial injuries in peritoneal area, 
deep penetrating wounds, and cysts or endometriomas 
which are consist of blood and endometrium-like tissue 
[12]. Dysmenorrhea, pelvic pain, urinary tract symp-
toms, and rectal bleeding are some symptoms by which 
endometriosis is diagnosed [13]. Endometriosis, by 
dint of hormonal induction, stimulation of neural path-
ways, inflammatory processes, and local bleeding, is able 
to cause pain but the exact mechanisms are not clear 
[12]. One of the most important causes of endometrio-
sis is infertility. According to the researches, 25–50% of 
women with infertility are diagnosed with endometriosis 
and also 30–50% of women with endometriosis are esti-
mated to be infertile [14]. It is also worth to mention that 
some studies declared that some of the lesions caused by 
endometriosis, especially the ovarian ones, appear to be 
monoclonal and being monoclonal is commonly known 
as a hallmark for neoplasia [15]. Therefore, endometrio-
sis, because of its unfavorable impacts on quality of life, 
work productivity, and fertility status, is an important 
disorder among the women in reproductive age [16]. In 
this review we gathered a great amount of evidence to 
inquire into the role of micro RNAs in inducing apopto-
sis and how this mechanism can be exerted for therapeu-
tic purposes for endometriosis.
Endometriosis pathogenesis
Generally, we put the name of endometriosis on an 
inflammatory estrogen-dependent condition in which 
endometrial-like tissues are found in some places other 
than its real position. Till now, scientists have not come 
to an agreement about the mechanism by which this 
condition is caused [17]. Some researchers have come 
up with some theories such as retrograde menstrua-
tion, coelomic metaplasia, and genetic alterations but 
still, further investigations are needed for clarifying the 
exact mechanisms. Observing the volume of blood and 
fragments of endometrial tissue which is refluxed dur-
ing a menstrual period in women with endometriosis 
led to the retrograde menstruation theory. According to 
this theory, these retreated endometrial fragments can 
be implanted into some other site than uterine and then 
grow into an ectopic endometrial-type tissue [18–20]. In 
another theory, the reason of this ectopic tissue’s produc-
tion is mainly attributed to metaplasia of the coelomic 
epithelium which itself is caused by environmental fac-
tors. As well, some scientists believe that the anatomical 
position of uterine, lymphatic or hematogenous spread of 
endometrial-related cells, and some other factors such as 
proton irradiation and dioxin might play a role in patho-
genesis of endometriosis [21].
In the immunity point of view, there is also a theory 
regarding the role of deficient immunity in endometrio-
sis. Haptoglobin and monocyte chemoattractant protein 
1 are two agents that might take part in causing endome-
triosis. In addition, some evidence accounts the abnor-
mal B cell, T cells, or natural killer cells as the responsible 
factor for this gynecological disease. Moreover, inflam-
mation caused by increased amounts of prostaglandins 
and cytokines is another possible reason that causes 
endometriosis [17, 18].
In addition, Arvanitis et  al. [22] showed the relation-
ship between CYP1A1, CYP19, GSTM1, and GSTT1 pol-
ymorphisms and endometriosis.
Apoptosis: a caspase‑dependent process
Generally, programmed cell death or PCD was first sep-
arated from apoptosis when necrosis was discovered as 
another pattern for cell death in early 1970s [23]. Apop-
tosis is an active exclusive molecular process which is 
essential in animals with a great number of cells and helps 
them to regulate the size of their tissues by modulating 
the number of their cells and also keeps them protected 
from the cells which can be threats to their homeostasis 
[24]. Any alteration in the mechanism of apoptosis can 
cause a complication: Hyper activation of apoptosis leads 
to some conditions like neurodegenerative diseases, defi-
ciency of the immune system, and ischemia–reperfusion 
injury and also the suppression of apoptosis can result 
in some other conditions including cancer, and autoim-
mune diseases [25].
A group of considerable morphological and biochemi-
cal alterations happen through this process and thereby 
cells first shrink and their nuclei condense, and then they 
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disintegrate into well-enclosed apoptotic bodies [26]. In 
a simple model, three phases can be named for apop-
tosis: initiation by two different mechanisms, genetic 
regulation by pro and anti-apoptotic genes, and effector 
mechanisms by caspases [27]. Commonly, there are two 
mechanisms that initiate apoptosis: extrinsic and intrin-
sic pathway. These two pathways are dependent to a 
group of homogeneous cysteine proteases named caspase 
family. Caspases are cell-killer proteases and till now, 10 
different kinds of them are discovered [28–30].
In the intrinsic pathway, two groups of mitochondrial 
proteins enter the cytosol in response to stimuli such as 
hypoxia, free radicals, and radiation. The first group of 
these proteins  causes activation in the caspase-depend-
ent mitochondrial pathway which leads to the activation 
of caspase-9. The other group causes a fragmentation 
and a condensation in the DNA and peripheral chroma-
tin of the nuclei, respectively [29, 31–33]. The extrinsic 
pathway, despite the intrinsic one, what stimulates the 
process is a ligand and therefore this pathway is depend-
ent to some receptors named death receptors. After 
the attachment of some ligand such as FasL, TNF, and 
TRAIL to the death receptors, a death signal is sent to 
the intracellular pathways and causes the formation and 
activation of a death-inducing signaling complex or DISC 
and caspase-8, respectively [33–36]. In the second phase, 
a motif of gene expression is created through a diversity 
of mechanisms by the initiators. There are two kinds of 
these expressed genes: pro-apoptotic (death genes) and 
anti-apoptotic (survival genes). Two major protein fami-
lies expressed by these genes are BCL-2 and p53 families. 
The BCL-2 is a family of proteins which has more than 20 
members and includes both survival and death proteins 
[37, 38]. The most known genes of this family are BCL-2 
itself, Bim, and the gene BAX which are respectively, 
anti-apoptotic, pro-apoptotic, and pro-apoptotic [39, 40].
MicroRNAs and apoptosis
As mentioned before, miRNAs are small evolutionary 
conserved RNAs which are able to alter the gene expres-
sion by affecting the gene’s related mRNA [5]. It is esti-
mated that miRNAs are responsible for more than 60% 
of gene regulations (coding genes). As well, these RNAs 
are able to suppress or induce apoptosis by altering its 
regulatory genes and thus take part in both intrinsic and 
extrinsic pathways. MiRNAs can influencing the gene 
expression in two ways: affecting mRNAs directly or 
indirectly by affecting other miRNAs [41, 42]. In extrinsic 
pathway, some miRNAs are reported to alter the expres-
sion of related ligands. For example, miR-21 is able to 
directly inhibit FasL and increase apoptosis or miR-130a 
is able to decrease the TRAIL resistance by the means 
of affecting some other miRNAs and augment apoptosis 
[43, 44].
Because of the important role of p53 and BCL-2 fami-
lies in regulating the intrinsic pathway, miRNAs can 
impact intrinsic pathway by changing the expression of 
the proteins of this two families [42]. Accumulating evi-
dence demonstrates that more than 20 kinds of miRNAs 
are directly regulating the pro-apoptotic p53 gene by 
binding to the 3′ untranslated region  of its mRNA. For 
instance, one of these miRNAs which can be produced 
by cancer cells is miR-504. These miRNA binds to two 
sites of the 3′-UTR region of p53 mRNA and therefore, 
causes the down-regulation of this gene [38, 45, 46]. 
Additionally, miRNAs can also take part in changing the 
expression of apoptotic caspases such as caspase-9 and 
caspase-3 which are blocked by miR-23a and miR-421, 
respectively [47, 48]. Therefore, miRNAs are involved in 
almost all the phases of apoptosis and are able to reduce 
or induce a cell’s apoptosis by influencing intrinsic path-
way, extrinsic pathway, and cascades. On the other hand, 
miRNAs can be used for diagnosis and treatment of many 
diseases such as cancer and even for prevention of some 
diseases (according to their potential for pathogenesis).
Apoptosis and endometrium: normal status
We can name three stages for the cycle of endometrium 
in menstruating women: proliferating, secretory, and 
menstrual stages [49]. The presence of apoptosis has 
been detected (in great extents) in the late secretory, 
menstrual, and (in very low extents) proliferative and 
early secretory stages [50–52]. Considering the role of 
estrogen and progestin in different phases of this cycle, 
creates this idea that they also have a part in regulating 
the apoptosis process. Vaskivuo et al. [53] showed that in 
the proliferative stage, there is an association between the 
concentration of estradiol in serum and down-regulation 
of apoptosis. Another involved factor in regulating the 
apoptosis during the phases of endometrial cycle is the 
BCL-2 protein produced from its gene. In endometrium, 
glandular and stromal cells express BCL-2 [54]. Otsuki 
et  al. [55] revealed that during the proliferating time, 
BCL-2 holds back the apoptosis and hence, it’s increased 
at the end of the first phase and reduced through the late 
secretory and menstrual stages. In spite of the expression 
amounts of BCL-2 in glandular cells, consistent immuno-
reactivity of this gene was observed in smooth muscles of 
the myometrium layer of the uterine [56]. This evidence 
demonstrates that the product of BCL-2 gene not only 
protects the glandular cells of endometrium but it also is 
important in the survival of smooth muscles of myome-
trium. In addition, Rogers et al. found that basal layer of 
the endometrium, in spite of the functional layer, shows 
more expression of BCL-2 gene and it’s because this layer 
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should be constant through the endometrial cycle. They 
also revealed that steroid hormones are one of the effec-
tive factors on altering the BCL-2 expression [57].
There also some other members of the BCL-2 protein 
family that studies has showed their impact on up or 
down-regulating the apoptosis in the different layers of 
endometrium during the endometrial cycle: BAX [51], 
BCL‐X [58], and BAK [59]. These mentioned proteins do 
their duty in mechanisms which are dependent or inde-
pendent from the action of BCL-2 [60]. All this together, 
these data insinuate that there is a dynamic coopera-
tion among a considerable number of members of the 
BCL-2 family which leads to initiation of apoptosis [60] 
and ovarian steroids may have a part in apoptosis by con-
trolling the expression of this members of BCL-2 family 
[55]. Another piece of machinery that is engaged in man-
aging the apoptosis is Fas/FasL system. Fas is a member 
of TNF/nerve growth factor receptor family which has 
45 kDa weight and is counted as a type I protein of the 
cell membrane [61]. FasL is the ligand of the Fas pro-
tein and is a 37 kDa protein. The interaction of Fas and 
its ligand is a key to the induction of apoptosis [62]. In 
the course of late proliferative stage, these proteins are 
being conserved in the Golgi apparatus and cytoplasmic 
vesicles but they are not able to interact; while in the 
second phase their release turns on the apoptosis [63]. 
Membrane‐bound and soluble are two kinds of FasLs. 
Some matrix metalloproteinases or MMP turn the first 
type into second type which is the active form [64]. In the 
endometrium, augmented function of MMPs before and 
throughout the menstruating stage (type 1, 3, and 9) [65] 
and during the secretory phase [66]. Moreover, BCL-2 
also has a role in managing the Fas/FasL related apopto-
sis: BCL-2 inactivates an enzyme called interleukin-con-
verting enzyme or ICE and thereby inhibits this pathway 
of apoptosis [67].
Apoptosis and endometrium: abnormal status 
of endometriosis
In endometriosis, not only the ectopic endometrium-
like tissue goes through a bunch of alterations but the 
eutopic endometrium also have some differences with 
the normal one [60]. These differences are consist of a 
diversity of abnormalities in structure, cell proliferation, 
immune elements, proteolytic enzymes and their inhibi-
tors, production of steroids and cytokines and proteins, 
and expression of different genes [68]. These differences 
can be a factor in the survival of the regurgitating endo-
metrial cells into the peritoneal cavity and thus help the 
progression of endometriosis [60]. Recently, the presence 
of apoptosis detected in women with endometriosis has 
been significantly considered. The number of entered 
survival cells into the peritoneal cavity is increased in 
these women because of the reduced amounts of apop-
tosis during the late secretory/menstrual and early pro-
liferative stages [69]. Expression of the proteins of the 
BCL-2 family and Fas proteins are the probable factors 
responsible for diminution of apoptosis in this disorder. 
Watanabe et  al. [54] compared the eutopic and ectopic 
endometrial tissues in women with endometriosis and 
found that in spite of the ectopic tissue, expression 
of BCL-2 has a cyclic pattern in glandular cells of the 
eutopic tissue. Jones et  al. [70] also observed an over-
expression of BCL-2 in stroma cells of the ectopic tis-
sues (which might be related to the augmented number 
of estrogen receptors of the stromal cells [71]). Another 
research conducted by Meresman et  al. [72] manifested 
that in the first phase of apoptosis expression of BCL-2 
and BAX are respectively elevated and absent and BAX 
is also overexpressed in the second phase in women with 
this disease compared to the healthy ones (Fig. 1).
We did not found any study comparing the expression 
of Fas in women with and without disease but a plenty 
of studies showed that the expression of FasL is higher 
in women having the disease [73]. Furthermore, some 
growth factors released from macrophages like platelet-
derived growth factor (PDGF) and transforming growth 
factor (TGF) are observed in peritoneal fluid of ill women 
more than disease-free women. These two growth factors 
stimulate stromal cells to express more FasL, thus, peri-
toneal macrophages also contribute to increase the apop-
tosis of immune cells. It means that ectopic endometroic 
cells express more FasL to protect themselves against 
the T cells of immune system [74, 75]. Additionally, 
higher extents of MMPs have been seen in sick women 
who can have a hand in decreasing the immune attacks 
by T lymphocytes of the host [76–78]. Another observed 
increased agent in the women with endometriosis is IL-8 
which is a chemokine inducing the stromal cell’s prolif-
eration and thereby aids the endometroic tissue to grow. 
Selam et  al. [79, 80] found that IL-8, as well, is instru-
mental in elevating the immunotolerance by the means 
of stimulating production of FasL. In addition to all of 
that, even the expression of BCL-2 and BAX is changed 
in peritoneal macrophages during the endometriosis and 
so the process of apoptosis is delayed and resistance of 
disease to immune system is increased [70, 81]. All this 
considered, apoptosis is a key player in pathophysiology 
of endometriosis.
MicroRNA and endometriosis: apoptotic activities
As mentioned before, miRNAs are able to affect apop-
tosis in many ways: they can regulate each step of apop-
tosis in both stimulatory and inhibitory manners. As a 
result, not only miRNAs are involved in the pathogen-
esis of several diseases but they also have the potential of 
Page 5 of 9Taghavipour et al. Cell Biosci           (2020) 10:12  
being used as biomarkers or therapeutic targets. Consid-
ering the pivotal role of apoptosis in endometriosis, we 
suggest that these RNAs might start a revolution in our 
understanding of endometriosis pathogenesis and help us 
provide more efficient diagnostic and therapeutic proce-
dures. Several kinds of research are conducted about dif-
ferent miRNAs involved in endometriosis by regulating 
apoptosis which we are going to represent some of them 
in this section.
Zhang et  al. [82] investigated the role of miR-141-3p 
in endometriosis and demonstrate that this miRNA is 
down-regulated in ectopic endometrium. MiR-141-3p is 
one of many miRNAs which affects apoptosis by reduc-
ing and inducing the expression of BCL-2 and Bax, 
respectively. This means that not only this miRNA can 
be considered as a pathogenesis-related factor but it also 
can be used as a biomarker and a therapeutic target for 
endometriosis. MiR-9 is another miRNA that is able to 
target the BCL-2 mRNA and thereby induce apopto-
sis. Dysregulation of this miRNA has been observed in 
some other gynecological diseases like ovarian cancer, as 
well. According to the down-regulation of this miRNA in 
endometriosis, Burney and colleagues suggest that this 
miRNA is somehow related to endometriosis pathogene-
sis [83]. Similarly, there are some other miRNAs (summa-
rized in Table 1) which their association to endometriosis 
has been examined and therefore, they have given us a 
new insight for the pathogenesis of this diseases. Further-
more, they are capable of taking part in treatment of 
endometriosis by targeting the oncogene mRNAs or by 
being the target of anti-cancer drugs.
MicoRNA and endometriosis: where are we 
standing?
Considering the differences existing between the 
expressed miRNAs of eutopic and ectopic endometrial 
tissue, miRNAs have the potential to be used as biomark-
ers in endometriosis [84]. A study showed that in endo-
metriosis cases, miR-34c-5p, miR-9, miR-34b  are down 
regulated in comparison to normal cases [83]. In addi-
tion, miR-483-5p and miR-629-3p are also two other 
miRNAs which their dysregulation in endometriosis has 
been confirmed [85]. Moreover, there are also several 
other miRNAs which are related to angiogenesis, inflam-
matory, cell proliferation, Steroidogenesis, and other 
mechanisms engaged in endometriosis and are being 
used as efficient biomarkers for the endometriosis diag-
nosis [84, 86–88]. However, involved miRNAs in apopto-
sis are not considered well in the field of diagnosis and 
thus, we suggest that investigating the efficacy of some 
miRNAs such as miR-21, miR-155, and miR-a125b is 
needed.
In treatment point of view, there are some studies that 
used miRNAs for targeting different genes and signal-
ing pathways engaged in apoptosis. for instance, adam-
mek et al. [89] tried on miR-145 on eutopic and ectopic 
endometrial stroma cells and found it useful. Another 
trial used miR-10b to target syndecan-1 to reduce the 
Fig. 1 Endometriosis and related factors and miRNAs
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cell invasiveness and observed considerable results 
[90]. As well, some other studies used miRNA such as 
miR-135a/b as therapeutic targets to treat the infertility 
caused by endometriosis [91]. There is also another trial 
that examined saponin, a component of Korean red gin-
seng, and found that it can target miR-21-5p and thereby 
be a therapeutic tool for endometriosis [92].
Notwithstanding all these evidence, there are still some 
obstacles in the way of using miRNAs as a common treat-
ment for endometriosis. Low stability and potential side 
effects are two major limitations of using these RNAs. 
Furthermore, the lack of proper route of administration 
and delivering approaches are some other barriers which 
nanotechnology is removing them out of the way by pro-
viding novel delivery systems [93]. All taken together, 
there is a lot of room in the field of using miRNAs for 
diagnosis and treatment of endometriosis for further 
investigations.
Conclusions
For years, scientists thought that 98% of our DNA was 
junk and not useful at all [94] but discoveries about the 
functions of RNAs transcribed from the non-coding 
parts of DNA made a revolution in our therapeutic and 
diagnostic approaches for many diseases. miRNAs are a 
kind of small non-coding RNAs which are known to have 
many parts in cellular processes (including apoptosis, cell 
proliferation, and inflammation) by regulating the gene 
expression. Hence, their contribution in pathogenesis of 
many diseases such as endometriosis is proven. Endo-
metriosis is a gynecological disorder among the women 
in reproductive age that might lead to cancer (in a very 
low percentage of women) and is also an important dis-
ease for causing several health problems such as infertil-
ity. Accumulative evidence has demonstrated the role of 
cell proliferation, apoptosis, and invasion in the progres-
sion of these diseases. In this review, we looked into the 
specific role of apoptosis and its related genes and path-
ways in endometriosis and tied to present an explanation 
of how miRNAs can affect endometriosis by their apop-
totic activities. What we found is that many miRNAs are 
involved and they are responsible for repressing apop-
tosis and progression of the disease. As a result, these 
miRNAs have the potential to be used in diagnostic and 
therapeutic decisions adopted for endometriosis. In the 
field of diagnosis, the current gold standard method for 
endometriosis is using surgery (laparoscopy) and direct 
observation [95]. Hence, miRNAs have the potential to 
be an ideal replacement for this dangerous and high-risk 
approach and plus, they can act more efficient for early 
detection of endometriosis. Although considering the 
many roles and functions that miRNAs have in cellular 
pathways, more investigations are needed for revealing 
their side effects after administration. Furthermore, find-
ing proper delivery systems which are able to increase the 
stability of miRNAs, protect them against degradation 
inside the body, and deliver them to the specific site of 
the disease are needed.
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miRNA: microRNA; RISC: RNA-induced silencing complex; PDGF: Platelet‐
derived growth factor; TGF: Transforming growth factor; PCD: Programmed 
Table 1 Experimental studies that investigated the role of miRNAs involved in regulating apoptosis in endometriosis
microRNA Expression Function Application References
miR-33b Down-regulated Facilitating caspase 3 activity Treatment and biomarker [96]
miR-191 Up-regulated Inhibition of TNF-alpha induced apoptosis and might contribute malignant 
transformation of endometriosis
Treatment and biomarker [97]
miR-503 Down-regulated Targeting BCL-2 mRNAs Treatment and biomarker [98]
miR-183 Down-regulated Reducing apoptosis Treatment and biomarker [99]
miR-29c Down-regulated Targeting c-JUN (a protein which regulates gene expression) Treatment and biomarker [100]
miR-148a – Affecting BCL-2 expression and caspase-3/9 through G protein coupled estro-
gen receptor/miR148a/human leukocyte antigen G signaling pathway
Treatment [101]
miR-210 Up-regulated Inhibition of apoptosis by targeting signal transducer and activator of tran-
scription 3
Treatment and biomarker [102]
miR-196b – Affecting BCL-2 expression, activation of caspase-3 and caspase-7 Treatment [103]
miR-363 Down-regulated Inducing apoptosis Treatment and biomarker [104]
miR-21-5p – Affecting the apoptotic potential of stromal cells. Treatment [92]
miR-9 Down-regulated Affecting BCL-2 expression Treatment and biomarker [83]
miR181c – NR4A-miR181c-Mst1 pathway regulates mitochondrial apoptosis Treatment [105]
miR-2861 Down-regulated Up-regulation of STAT3 and MMP2 and inducing apoptosis Treatment and biomarker [106]
miR-141-3p – Down-regulation the expression of Bcl-2 and raising the expression of Bax 
and contributing to the apoptosis of ectopic ESCs
Treatment [82]
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